Light therapy solution for Dry Eye Disease
EssilorLuxottica Instruments Division - Sales Excellence Program
INTERNAL USE ONLY - CONFIDENTIAL
🇨🇦 Canada Market Messaging: In Canada, you can directly mention Dry Eye Disease (DED) as the primary clinical indication. Position eye-light® as the leading comprehensive DED treatment solution with dual therapy (OPE™ IPL + LM™ LLLT) that addresses the root cause while offering broader therapeutic applications.
Key Differentiators:
• Dual Technology Leadership: OPE™ IPL (Optimal Power Energy™) + LM™ LLLT (Light Modulation™ Low-level Light Therapy/Photobiomodulation) = most comprehensive DED platform
• DED is Multifactorial: Contact Lens-induced DED, Iatrogenic DED from surgery, unstable tear film causing suboptimal surgical outcomes
• Clinical Validation: Featured in TFOS DEWS III (rare recognition by trade name)
• Root Cause Treatment: Addresses underlying mechanisms, not just symptoms
Focus Your Sales Efforts Strategically
Optometrists - High-End Clinics with DED Focus
Why Priority: Optometrists are primary DED care providers in Canada, seeing massive patient volumes with Dry Eye Disease. eye-light® dual technology (OPE™ IPL + LM™ LLLT) provides comprehensive DED treatment with competitive pricing versus leading platforms (InMode, LUVO Darwin), with ability to directly market for DED.
Key Benefits Alignment:
• OPE™ IPL treats meibomian gland dysfunction (leading cause of evaporative DED)
• LM™ LLLT (Red wavelength): Multiple mechanisms of action including HIF-1alpha factor (hypoxia), lipid flow improvement (through heat), mitochondrial activity enhancement (ATP production), and overall inflammation markers reduction
• Can directly advertise and market for Dry Eye Disease treatment
• Competitive pricing versus leading platforms fits optometry budgets
• Minimal consumables (masks last 500 treatments @ $18 CAD per treatment) ensures strong DED treatment margins
• Training and marketing support helps launch DED service line quickly
Sub-specialty Focus: Dry eye specialists, specialty contact lens fitters (CL-related DED), comprehensive optometry building DED practice
Independent Practices: Emphasize DED epidemic opportunity (1 in 4 Canadians), new revenue stream, differentiation
Regional Key Accounts: Standardized DED protocols across locations, enterprise DED program
National Key Accounts: National DED treatment capability, cost-per-location advantage, brand positioning as DED solution leader
Ophthalmologists - Cornea/External Disease Specialists
Why Priority: Cornea specialists in Canada manage complex DED cases, often after patients have failed conservative treatments. eye-light® provides advanced treatment option for their most challenging DED patients.
Key Benefits Alignment:
• Medical-grade DED treatment for refractory cases
• Dual technology (OPE™ IPL + LM™ LLLT) for complex DED presentations
• Reduces reliance on chronic medication management for DED
• Can treat both MGD and aqueous deficiency components
• Premium construction matches specialist quality expectations
Sub-specialty Focus: Cornea/external disease specialists, tertiary referral centers for DED, academic medical centers
Independent Practices: Position as solution for complex DED referrals that have failed other treatments
Regional Key Accounts: Standardized advanced DED treatment for regional referral network
National Key Accounts: Enterprise-wide advanced DED management protocols
Ophthalmologists - Cataract/Refractive Surgery & Oculoplastics
Why Priority: Surgical practices must manage DED pre/post-operatively for optimal outcomes. Uncontrolled DED leads to poor surgical results, patient dissatisfaction, and IOL calculation errors. Unstable tear film due to DED is the cause of suboptimal surgical outcomes.
Key Benefits Alignment:
• Pre-operative DED optimization improves surgical outcomes and IOL accuracy
• LLLT proven prophylactically7,8 (1 session pre-op / 1 post-op) in healthy patients to prevent post-op iatrogenic DED
• Healthy patients benefit: Stabilizes tear film ahead of surgery for better biometric calculations and surgical outcomes
• Non-disruptive to normal surgery workflow
• Post-operative DED management (common after cataract/LASIK)
• Oculoplastics: periorbital inflammation and aesthetic applications
• Reduces surgical complications related to ocular surface disease
• Dual cash-pay revenue: therapeutic DED + aesthetic LLLT applications
Sub-specialty Focus: Cataract surgeons, refractive surgeons (LASIK/PRK), oculoplastic surgeons
Independent Practices: Emphasize better surgical outcomes, reduced DED-related complications, aesthetic revenue
Regional Key Accounts: Standardized pre/post-op DED protocols across surgical centers
National Key Accounts: Enterprise surgical DED management, premium patient experience differentiation
General Optometry & Ophthalmology Without DED Focus
Why Lower Priority: Practices without specific focus on DED management may not see enough qualifying patients to justify investment. Better to focus on practices actively building or having DED patient volumes.
Key Benefits Alignment (When Applicable):
• Building DED service line to capture growing market
• Competitive differentiation in saturated markets
• Future-proofing as DED awareness grows
When to Pursue: Practice expressing interest in adding DED services, competitive market requiring differentiation, high-growth practice looking for new revenue streams
Opticians - Optical Retail
Why Lower Priority: Opticians don't diagnose or treat DED. Very limited application unless co-located with medical practice.
When to Pursue: Only if optical chain has affiliated medical practices or is explicitly building DED services division
Highest ROI Focus: Optometrists building DED specialty practices (1 in 4 Canadians have DED - massive opportunity, can directly market DED treatment)
High-Value Opportunities: Cornea specialists (complex DED), surgical practices (pre/post-op DED, iatrogenic prevention), oculoplastics (DED + aesthetics)
Selective Pursuit: General practices only if showing clear interest in building DED services
Avoid: Practices without DED patient volume or service expansion plans
Canada Advantage: Ability to directly mention and market "Dry Eye Disease" treatment makes optometry targeting even stronger than USA market
Understand Before You Sell
Purpose: Uncover DED patient volume opportunity - position as solution for epidemic condition
Follow-up: How are you currently managing DED patients? Are they satisfied with their current treatment options, or are many still struggling?
Purpose: Identify pain points (patient compliance with drops, limited efficacy, cost of chronic treatments)
Follow-up: How many of your DED patients are truly getting relief versus just managing symptoms?
Purpose: Assess current technology adoption and competitive landscape
Follow-up: If yes: What do you like about it? What's missing? If no: What's held you back from adding this treatment modality for your DED patients?
Purpose: Position 30% cost advantage against Lumenis (US market leader only, not global)
Follow-up: Are you familiar with what similar light therapy devices for DED cost in the market? eye-light® offers professional-grade dual technology at 30% less than single-technology competitors.
Purpose: Position dual-technology advantage (OPE™ IPL + LM™ LLLT) for diverse DED patient needs. LLLT has been shown to enhance IPL outcomes when used jointly, and is superior to IPL when used alone (painless, risk-free for all skin types1).
Follow-up: Would having both IPL for meibomian gland dysfunction and LLLT for cellular healing in one device be valuable for your DED practice?
Purpose: Highlight premium construction and upgradable system
Follow-up: Have you encountered issues with devices becoming obsolete or requiring frequent replacement?
Connect Features to Customer Outcomes
Feature: Optimal Power Energy™ Intense Pulsed Light - painless treatment of periorbital area, reaches deeper tissue without protective gel
Benefit: Treats meibomian gland dysfunction, improves gland secretion, reduces ocular surface inflammation, enhances tear film stability
Impact: Addresses root cause of evaporative DED → Improved patient comfort → Long-term symptom relief → Streamlined gel-free treatment
Discovery Questions:
• What percentage of your DED patients have meibomian gland dysfunction?
• Would eliminating gel application save time and improve patient experience?
Feature: Light Modulation™ Low-level Light Therapy (Photobiomodulation) with Red wavelength - non-invasive, painless, risk-free for all skin types
Benefit: Multiple mechanisms of action (MOA):
• HIF-1alpha factor (hypoxia-related)2
• Lipid flow improvement (through heat)
• Mitochondrial activity enhancement (ATP production)
• Overall inflammation markers reduction
• Enhances IPL outcomes when used jointly4,5
• Superior to IPL when used alone6
Impact: Enhanced cellular function for tear production → Visible DED symptom improvement → Prophylactic use in healthy surgical patients (1 pre-op/1 post-op) prevents iatrogenic DED and improves outcomes
Discovery Questions:
• How important is it that DED patients see quick symptom improvement to maintain treatment compliance?
• Would offering both therapeutic DED and prophylactic surgical protocols expand your patient base?
Feature: Stainless steel body, upgradable OS, developed in-house by Espansione Group for quality control
Benefit: Long-term durability, future-proof technology, no obsolescence concerns, ongoing support and development
Impact: Protected investment → Consistent performance for years → Lower total cost of ownership
Discovery Questions:
• What's your typical equipment replacement cycle?
• Have you had devices become outdated before their time?
Turn Concerns Into Opportunities
Initial Rebuttal: "That's excellent - you're already treating DED with light therapy. How are you finding your current system? Any features you wish it had or patients who don't respond as well as you'd like?"
Approach:
• Listen for gaps: only IPL with no LLLT options, patient demand exceeds capacity, want alternatives for non-responders, concerns about single-modality limitation
• Position eye-light® as complementary: Consider buying eye-light® as an LLLT-only device to match their IPL, or buy-back program to retire their IPL (if not immediately, after LLLT trial)
• LLLT wavelengths (Red) provide additional therapeutic pathways that IPL-only platforms don't offer
• LLLT enhances IPL outcomes when used jointly4,5; superior to IPL alone6
Proof Point: "eye-light® gives you both OPE™ IPL for MGD AND LM™ LLLT (Red wavelength) for ocular surface healing - comprehensive treatment platform. Plus, our masks last 500 treatments at only $18 CAD per treatment cost. Many DED-focused practices run multiple light therapy devices to handle patient volume, offer different protocols for non-responders, or provide both technologies at different locations."
Initial Rebuttal: "I understand the skepticism - DED outcomes definitely vary by device and protocol. What specifically have you heard or experienced?"
Approach:
• Acknowledge that not all IPL devices are equal for DED treatment
• Explain OPE™ (Optimal Power Energy™) technology - customizable parameters for different DED presentations, gentle on periorbital area
• Emphasize eye-light®'s unique combination: when IPL alone isn't enough for certain DED patients, LLLT provides additional therapeutic pathway
• Direct them to literature: We have comparative studies proving superiority to E>Eye (ESW) and other IPL-only devices; wide number of RCTs1,10,11 proving efficacy for DED
• Growing body of clinical evidence supports light therapy for DED
Proof Point: "Multiple clinical studies show IPL's effectiveness for meibomian gland dysfunction and evaporative DED. This evidence resulted in TFOS DEWS III recognition of eye-light® by trade name (rare for a clinical guideline to mention specific product). We can send over our scientific compendium and actual published papers. Plus, having LLLT as a backup or complementary option means you're not limited to one approach for complex DED cases."
Initial Rebuttal: "I appreciate being mindful of budget. Let's look at this as an investment in your DED practice - what would you charge per treatment session?"
Approach:
• Calculate ROI together. Typical DED protocols: 4-6 sessions per patient
• With the growing DED epidemic, treating just 2-4 patients per day, most practices recover investment in under 12 months
• Emphasize competitive acquisition cost versus leading platforms
• Minimal consumables (masks last 500 treatments at $18 CAD per treatment) means nearly every treatment dollar flows to profit after payoff period
• Plus DED is a growing market with increasing patient awareness
Proof Point: "With the DED epidemic affecting millions of Canadians, at just 2 DED patients daily, you'll recover your investment in less than a year. Masks lasting 500 treatments means minimal ongoing costs. Plus, training and marketing support are included."
Initial Rebuttal: "I understand the concern about consumable costs - let's look at what that $9,000 CAD actually delivers in terms of treatment capacity and cost-per-treatment."
Approach:
• Frame the mask as high-capacity medical device, not traditional consumable
• Each mask delivers 500 full treatments before replacement
• Cost analysis: $9,000 CAD ÷ 500 treatments = $18 CAD cost per treatment
• Compare to alternatives: traditional disposable IPL handpieces or single-use consumables from other platforms often cost $50-100+ per treatment
• eye-light®'s approach dramatically reduces per-treatment consumable costs
• Mask longevity means: (1) Less frequent purchasing/ordering disruption, (2) Fewer supply chain concerns, (3) Predictable cost structure for business planning
• At typical DED treatment pricing ($200-400 per session in Canada), $18 consumable cost represents only 4.5-9% of revenue - extremely favorable margin
• When positioned against competitive platforms, our consumable costs are actually LOWER on per-treatment basis despite higher upfront mask cost
Proof Point: "At 500 treatments per mask, your cost is only $18 CAD per treatment. If you're charging $300 per session, that's 6% of revenue for consumables - one of the lowest in the industry. Compare that to platforms using disposable components at $50-100 per treatment. Over 500 treatments, you're saving $16,000-41,000 CAD versus higher per-treatment consumable costs. The math strongly favors our approach."
Counter-Question: "What matters more to your practice economics - a lower upfront consumable cost, or lower cost-per-treatment over time? Most practices find the $18 per treatment consumable cost creates much better margins than platforms with cheaper masks but higher per-use costs or frequent replacements."
Initial Rebuttal: "Really? Studies show 1 in 4 Canadians suffers from Dry Eye Disease. How many patients per day mention symptoms like burning, grittiness, or redness?"
Approach:
• Expand their thinking - many DED patients are undiagnosed or under-treated
• Screen comprehensively: anyone with red eyes, contact lens discomfort, screen-related symptoms, meibomian gland issues
• Many don't currently seek treatment because they don't know effective options exist
• Once you offer eye-light®, DED patients will find you
Proof Point: "DED affects an estimated 25-30% of Canadians. That's potentially hundreds of your existing patients. Once you start screening and offering advanced treatment, you'll discover the patient volume."
Initial Rebuttal: "Great question - let's talk about what your DED patients are actually experiencing with drops. How compliant are they with their drop regimens?"
Approach:
• Eye drops for DED often cost patients hundreds to thousands annually with no end in sight - it's symptom management, not addressing root cause
• Your practice makes zero revenue from those prescriptions
• We have a study proving superiority of 3 sessions of eye-light® for DED against a regimen of daily 3x eye-drops (in max compliance, which is not the case for real life) for 6 months
• eye-light® addresses underlying inflammation and MGD through improved circulation and cellular healing
• DED patients prefer finite treatment protocols over lifelong drop dependency
• eye-light® can be an adjunct to drops initially, but it's likely the patient will not need drops after therapy
• Plus, OPE™ IPL reaches deeper tissue without needing protective gel, making treatments more comfortable and effective
Proof Point: "Our study proves 3 eye-light® sessions are superior to 6 months of daily drops (even in perfect compliance scenario). Many DED patients spend more annually on prescription drops than a complete eye-light® treatment series - and they're still dependent on drops. With light therapy, you're offering potential long-term relief while generating practice revenue instead of sending patients to pharmacies."
Initial Rebuttal: "That's exactly why we built upgradeability into eye-light® from day one. Tell me about your concerns with technology obsolescence."
Approach:
• Technologies take 20-25 years to be replaced by new tech
• LLLT/PBM is just at its beginnings for DED applications - it has just reached global consensus/recognition for DED
• The time to be ahead of the curve before it becomes massively adopted is now
• Explain upgradable operating system keeps device current with software advances
• Stainless steel construction lasts decades
• IPL and LLLT are established, proven technologies for DED (not experimental)
• Device developed entirely in-house by Espansione Group means ongoing support and development
• DED prevalence is increasing, not decreasing - this market will only grow
Proof Point: "Light-based therapy for DED has 15+ years of clinical validation and growing adoption worldwide. The DED epidemic ensures this technology will remain relevant. Technologies take 20-25 years to be replaced - LLLT/PBM is just at its beginnings and has just reached global consensus. Now is the time to lead, not follow. The eye-light®'s upgradable platform means you get future enhancements without replacing the entire device."
Initial Rebuttal: "I completely understand - training time is valuable. What if I told you most operators become proficient in under an hour?"
Approach:
• Emphasize intuitive interface, automated software (calculates treatment duration)
• 15-minute sessions fit easily into schedule
• Can be delegated to technicians for DED treatments, freeing doctor time
• We provide comprehensive training and ongoing support included in the purchase
• Device is designed for ease of use
• Plus, no gel application needed with our OPE™ IPL technology, which simplifies the workflow even more
Proof Point: "We include full training with purchase, and most practices have staff performing DED treatments independently within a week. The automated protocols and gel-free application minimize the learning curve."
Win Against Key Competitors
Their Strength: Strong presence in aesthetic market with crossover to DED, IPL technology, established in medical aesthetics giving brand credibility
Our Advantage:
• Purpose-built specifically for DED treatment (not aesthetic crossover)
• DUAL technology - IPL PLUS LLLT with Red wavelength for comprehensive DED treatment
• Light Modulation™ technology for enhanced therapeutic effect
• Upgradable system allowing practices to start with IPL or LLLT and add the other later
• Dedicated DED clinical focus versus aesthetics-first approach
Positioning: "InMode has strong brand in aesthetics and brought their IPL technology to Dry Eye treatment. eye-light® is purpose-built specifically FOR Dry Eye - we offer both OPE™ IPL technology for MGD AND Light Modulation™ LLLT with Red wavelength that InMode doesn't provide. For complex DED cases or patients who don't fully respond to IPL alone, you have additional treatment modalities. Plus our system is upgradable - start with what your practice needs most (IPL or LLLT) and add the other technology later as your DED services grow. You get dedicated DED treatment platform with more therapeutic options versus aesthetic device adapted for Dry Eye."
⚠️ Trap to Avoid: Don't dismiss InMode's aesthetic success - acknowledge their strong brand and IPL quality. The differentiation is purpose-built DED focus versus aesthetic crossover, and dual technology (IPL + LLLT) versus IPL only. Position as "comprehensive DED treatment platform" not "better IPL."
Their Strength: Clarion's established distribution network in Canada, integrated approach, known brand in Canadian market
Our Advantage:
• Dual technology platform (IPL + LLLT) provides more treatment versatility
• Light Modulation™ LLLT with Red wavelength for targeted therapy
• Upgradable system flexibility
• Patented technology backed by clinical research
• Masks lasting 500 treatments reduce ongoing costs
• EssilorLuxottica backing provides long-term support and service infrastructure
Positioning: "LUVO Darwin through Clarion is solid equipment with good Canadian support. Key difference is treatment versatility: eye-light® provides BOTH OPE™ IPL for MGD AND Light Modulation™ LLLT with Red wavelength - giving you multiple treatment modalities for different DED presentations. Our upgradable platform lets you start with one technology and add the other as practice develops, versus single-technology commitment. Additionally, EssilorLuxottica's backing provides long-term equipment support and service infrastructure. You get comprehensive dual-technology DED platform with flexibility to grow your services over time."
⚠️ Trap to Avoid: Respect Clarion's strong Canadian presence and distribution. Focus differentiation on dual technology capability and treatment versatility rather than attacking their distribution or service. Position as "more therapeutic options" not "better equipment."
Their Strength: Market leader in the US only, nowhere else, strong brand recognition in US, extensive clinical data for Dry Eye, invented IPL technology
Our Advantage:
• 30% lower acquisition cost
• Same OPE™ IPL quality, PLUS we have LLLT (they don't)
• They can't offer LLLT/PBM - and that's where the future is
• Upgradable system, minimal consumables (masks last 500 treatments)
• Broader treatment versatility
Positioning: "Lumenis invented IPL and is respected in the US market, but they're not a global leader. eye-light® delivers the same OPE™ IPL technology for MGD and DED at 30% less - and adds Light Modulation™ LLLT with Red wavelength that Lumenis cannot offer. For complex DED cases or non-responders, you have additional therapeutic options. You get more treatment versatility for significantly less investment. The future is LLLT/PBM - that's where we should shift the conversation."
⚠️ Trap to Avoid: Don't bash Lumenis - they invented IPL. Acknowledge their clinical validation and respect their US market position, emphasize we use the same OPE™ IPL core technology, then pivot to our dual-technology advantage and price-value equation. Position as "more DED treatment options for less investment." Focus on what they lack (LLLT) not attacking their IPL. They are US leader only, not global.
Their Strength: Very low price point, easy online purchase, no prescription needed, marketed for DED relief
Our Advantage:
• Medical-grade device with professional power and wavelengths
• Proven clinical efficacy
• Patented Light Modulation™ technology
• Combined with medical-grade OPE™ IPL for MGD
• Supervised professional treatment protocols
Positioning: "Those consumer LED masks marketed for Dry Eye on Amazon don't work for real DED - they lack the power, precise wavelengths, and clinical validation needed for actual results. They're not safe. They're not medical devices (they're basically a toaster - it's like trying to achieve laser eye correction with a $10 laser pointer you play with cats with). eye-light® is a medical device with patented photobiomodulation technology backed by clinical research. Plus, we combine professional LLLT with OPE™ IPL specifically for meibomian gland dysfunction - something no consumer device can offer for DED treatment. Patients are free to try consumer devices and see they don't work."
⚠️ Trap to Avoid: Don't be dismissive of DED patients who've tried these - they were desperately seeking relief. Instead, empathize with their struggle, then educate on the difference between consumer gadgets and medical-grade DED treatment. Focus on clinical efficacy, professional power levels, and addressing root causes (MGD, inflammation) versus false promises.
Their Strength: Lower price point for basic IPL, simpler technology
Our Advantage:
• Dual technology platform for diverse DED presentations
• Upgradable system
• Premium construction
• Comprehensive treatment options
Positioning: "Basic IPL devices give you one tool for DED - treating MGD. eye-light® gives you two complementary technologies - IPL for meibomian gland dysfunction and vascular effects, plus LLLT for ocular surface inflammation and cellular healing. When a DED patient doesn't respond fully to IPL alone, you have alternatives without referring them elsewhere."
⚠️ Trap to Avoid: Don't compete solely on price with cheaper devices. Emphasize clinical versatility for different DED phenotypes, premium construction, and long-term value. "You get what you pay for" - position eye-light® as professional-grade DED solution.
Their Strength: No capital investment required, familiar protocols
Our Advantage:
• Superior DED outcomes
• New revenue stream
• Practice differentiation
• Patient satisfaction
• Reduced reliance on chronic medications
• Addresses root cause vs. symptom management
Positioning: "Traditional treatments like artificial tears and prescription drops have their place, but they're symptom management that costs DED patients hundreds to thousands annually - with zero revenue to your practice. eye-light® addresses the root causes of DED - MGD and inflammation - through improved meibomian gland function and cellular healing. Our OPE™ IPL technology reaches deeper tissue without protective gel. You're offering potential long-term DED relief while building practice revenue. With 1 in 4 Canadians suffering from DED, this is a significant market opportunity."
⚠️ Trap to Avoid: Don't dismiss traditional DED approaches - position as complementary. "Some DED patients need both" message. Focus on unmet needs (patients still suffering with drops only), revenue opportunity (you make nothing from prescriptions), and patient preferences for addressing root causes versus lifelong drop dependency.
Guide Decisions, Don't Push
Best used: With growth-oriented practices looking to build their DED specialty
"With 1 in 4 Canadians suffering from Dry Eye Disease and the condition only getting more prevalent with digital device use, this is a massive and growing market. Based on your patient volume, if you treated just 2-3 DED patients daily with our typical 4-6 session protocols, you'd generate significant annual revenue. The eye-light® pays for itself in 8-12 months, and with masks lasting 500 treatments, your ongoing costs are minimal. Does positioning your practice as a DED treatment center make strategic sense?"
Best used: With clinically-focused doctors who prioritize DED patient outcomes
"You mentioned wanting to provide better solutions for your Dry Eye patients. eye-light® gives you both IPL for MGD and LLLT for ocular surface healing in one device - so whether a DED patient has evaporative, aqueous deficient, or mixed presentation, you have treatment options. How important is it that you can customize DED treatment for each patient's specific condition?"
Best used: With competitive practices wanting to differentiate in the DED market
"More practices are adding DED light therapy every month as patient awareness grows. The question is whether you want to lead this trend in your area or follow. eye-light® positions you as a comprehensive Dry Eye treatment center offering advanced therapeutic solutions. How do you want your practice to be known when DED patients are researching treatment options?"
Best used: When prospects need to review literature to be convinced
"Many clinicians need to review the literature before making equipment decisions. We have:
• Comparative studies proving eye-light®'s superiority to E>Eye and other IPL-only devices
• Wide number of RCTs proving efficacy for DED
• TFOS DEWS III recognition1 (rare for guideline to mention specific product by trade name)
• We can send you our scientific compendium and actual published papers
Additionally, we offer several engagement options:
• Connect you to current users/KOLs via direct call
• Connect you to the Espansione Scientific Community on WhatsApp (current users and scholars)
• Direct you to webinars on our website featuring world-class KOLs presenting their clinical trial results
Would any of these resources help you make a confident, evidence-based decision?"
Best used: When skepticism remains or they want tangible proof with their DED population
"I can tell you're interested but want to see results with your own DED patients. What if we arranged a demonstration day at your practice? You could treat a few Dry Eye patients, see the symptom improvement firsthand, and your staff can experience how easy it is to operate. We include comprehensive training and marketing support with every purchase. Would a demo with your actual DED patients help you make a confident decision?"